Abstract
Aims
Both surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) are established options to treat aortic valve stenosis. We present the outcome of the complete cohort of all patients undergoing SAVR or TAVI in Germany during the calendar year 2019.
Methods and results
Data concerning all isolated aortic valve procedures performed in Germany in 2019 were retrieved from the mandatory nationwide quality control program: 22,973 transvascular (TV)-TAVI procedures, 7905 isolated SAVR (iSAVR), and 1413 transapical (TA)-TAVI. Data was complete in 99.9% (n = 32,156). In-hospital mortality after TV-TAVI (2.3%) was significantly lower when compared with iSAVR (2.8%, p = 0.007) or TA-TAVI (6.3%; p < 0.001). Expected mortality was calculated with a new version of the German Aortic valve score (AKL Score) based on the data of either catheter-based (AKL-CATH) or surgical (AKL-CHIR) aortic valve replacements in Germany in 2018. TV-TAVI and iSAVR both showed lower observed mortality in 2019 than expected based on their respective performance in 2018, yielding an observed/expected (O/E) mortality ratio < 1. This was particularly apparent for patients at low risk. After exclusion of emergency procedures, in-hospital mortality after TV-TAVI (2.1%) and after iSAVR (2.1%) was identical, even though patients undergoing TV-TAVI showed a considerably higher perioperative risk profile.
Conclusion
After excluding emergency procedures, in-hospital mortality of TV-TAVI and iSAVR in 2019 in Germany was identical. In 2019, TV-TAVI and iSAVR both show lower matched mortality ratios compared with 2018, which suggests technical improvements of both therapies.
Graphical abstract
Similar content being viewed by others
References
Möllmann H, Husser O, Blumenstein J et al (2020) Lower mortality in an all - comers aortic stenosis population treated with TAVI in comparison to SAVR. Clin Res Cardiol 109:611–615. https://doi.org/10.1007/s00392-019-01548-1
Gaede L, Blumenstein J, Liebetrau C et al (2018) Outcome after transvascular transcatheter aortic valve implantation in 2016. Eur Heart J 39:667–675. https://doi.org/10.1093/eurheartj/ehx688
Smith C, Leon M, Mack M, Miller D, Moses J, Svnesson L, Tuzcu E, Webb J, Fontana G, Makkar R, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani V, Corso P, Pichard A, Bavaria J, Herrmann H, Akin J, Anderson W, Wang D, PS for the PTI (2011) Transcatheter versus surgical aotic-valve replacement in high-risk patients. N Engl J Med 364:2187–2198
Thourani VH, Kodali S, Makkar RR et al (2016) Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 387:2218–2225. https://doi.org/10.1016/S0140-6736(16)30073-3
Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376:1321–1331. https://doi.org/10.1056/NEJMoa1700456
Mack M, Leon M, Thourani V et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695–1705. https://doi.org/10.1056/NEJMoa1814052
https://www.iqtig.org/berichte/bundesauswertung/. Website last accessed on September 11th, 2020
Gaede L, Kim W-K, Blumenstein J et al (2017) Temporal trends in transcatheter and surgical aortic valve replacement. Herz 42:316–324. https://doi.org/10.1007/s00059-016-4461-1
Gaede L, Blumenstein J, Liebetrau C et al (2019) Transvascular transcatheter aortic valve implantation in 2017. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01509-8
Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC / EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology ( ESC ) and the European. Eur Heart J 38:2739–2791. https://doi.org/10.1093/eurheartj/ehx391
Acknowledgements
We thank Elizabeth Martinson, Ph.D., of the KHFI Editorial Office for her editorial assistance.
Funding
No Funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
HM received speaker honoraria/proctor fees from Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, and SMT; OH and JB received proctor fees from Boston Scientific; LG receives speaker honoraria from Edwards and Abbott; CWH receives honoraria from Medtronic as International Advisory Board Member. HN.
Ethical approval
The study compliances with ethical standards. The data derives from the anonymous mandatory nationwide quality control program available online.
Rights and permissions
About this article
Cite this article
Gaede, L., Blumenstein, J., Husser, O. et al. Aortic valve replacement in Germany in 2019. Clin Res Cardiol 110, 460–465 (2021). https://doi.org/10.1007/s00392-020-01788-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-020-01788-6